WS Investor
24 Feb 2026, 18:00
Galapagos reports €3.0bn cash position after strategic reset in 2025
Feb. 23, 2026 — Galapagos NV said it ended 2025 with approximately €3.0 billion in cash and financial investments, following a strategic reset aimed at repositioning the company for long-term value creation.
The company is progressing with the wind-down of its cell therapy activities, expected to be substantially completed by the end of the third quarter of 2026. Related one-time restructuring cash costs have been reduced to an updated range of €125–175 million, with €25 million in additional one-off costs anticipated in 2026.
Galapagos expects its 2026 year-end cash position to be between €2.775 billion and €2.850 billion and aims to be cash flow neutral to positive by the end of 2026, excluding business development activity and currency effects.
Management said the company will transition to a lean structure of 35–40 employees by end-2026 and focus on a business development-led growth strategy, leveraging its collaboration with Gilead Sciences to build a new pipeline of novel therapeutics targeting areas of high unmet medical need.
Feb. 23, 2026 — Galapagos NV said it ended 2025 with approximately €3.0 billion in cash and financial investments, following a strategic reset aimed at repositioning the company for long-term value creation.
The company is progressing with the wind-down of its cell therapy activities, expected to be substantially completed by the end of the third quarter of 2026. Related one-time restructuring cash costs have been reduced to an updated range of €125–175 million, with €25 million in additional one-off costs anticipated in 2026.
Galapagos expects its 2026 year-end cash position to be between €2.775 billion and €2.850 billion and aims to be cash flow neutral to positive by the end of 2026, excluding business development activity and currency effects.
Management said the company will transition to a lean structure of 35–40 employees by end-2026 and focus on a business development-led growth strategy, leveraging its collaboration with Gilead Sciences to build a new pipeline of novel therapeutics targeting areas of high unmet medical need.